Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/16/2019 07/17/2019 07/18/2019 07/19/2019 07/22/2019 Date
88.03(c) 89.67(c) 92.46(c) 92.7(c) 92.5 Last
5 782 276 7 574 355 11 414 436 7 575 131 4 107 822 Volume
+0.30% +1.86% +3.11% +0.26% -0.22% Change
More quotes
Financials (USD)
Sales 2019 46 888 M
EBIT 2019 13 811 M
Net income 2019 10 249 M
Debt 2019 17 311 M
Yield 2019 3,21%
Sales 2020 48 974 M
EBIT 2020 14 861 M
Net income 2020 9 444 M
Debt 2020 11 529 M
Yield 2020 3,34%
P/E ratio 2019 24,7x
P/E ratio 2020 21,8x
EV / Sales2019 4,89x
EV / Sales2020 4,56x
Capitalization 212 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (67.2%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
09/05Presentation
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
10:14aNOVARTIS : key multiple sclerosis Product Gilenya approved in China
AQ
01:16aNOVARTIS : Sandoz announces first patient enrolled in clinical study for propose..
GL
07/19ALCON : Novartis delivers strong sales, double digit core operating income growt..
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19NOVARTIS : key multiple sclerosis product Gilenya® approved in China
PU
07/18EUROPE : ECB report eases earnings pain for European stocks
RE
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18GLOBAL MARKETS LIVE : Microsoft, Qualcomm, Netflix, Facebook…
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18Weak Earnings, Trade Tensions Weigh on Global Stocks
DJ
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2018
Technically solid
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
12:38pGLAXOSMITHKLINE : ViiV Healthcare Finds Positive Data In HIV Drug Study
DJ
12:04pBAYER : Iberogast Drug Is Safe
DJ
11:22aFDA Approves Multiple Applications for Generic Version of Lyrica
DJ
10:43aALLERGAN : Form 8.3 -
DJ
10:18aMERCK AND : Bayer sells Dr. Scholl's footcare brand to Yellow Wood Partners
RE
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 93,30  $
Last Close Price 92,50  $
Spread / Highest target 16,2%
Spread / Average Target 0,87%
Spread / Lowest Target -17,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS24.78%216 273
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
MERCK AND COMPANY6.52%209 550